NeoGenomics (NASDAQ:NEO) Stock Price Up 7.4%

Shares of NeoGenomics, Inc. (NASDAQ:NEO) traded up 7.4% during trading on Tuesday . The company traded as high as $14.47 and last traded at $14.41. 367,691 shares traded hands during trading, a decline of 59% from the average session volume of 894,080 shares. The stock had previously closed at $13.42.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the stock. TD Cowen lowered their price target on shares of NeoGenomics from $22.00 to $19.00 and set an “outperform” rating on the stock in a research report on Friday, December 29th. Needham & Company LLC boosted their price target on shares of NeoGenomics from $21.00 to $24.00 and gave the stock a “buy” rating in a research report on Wednesday, February 21st. William Blair restated an “outperform” rating on shares of NeoGenomics in a research report on Wednesday, February 21st. The Goldman Sachs Group boosted their price target on shares of NeoGenomics from $17.00 to $19.00 and gave the stock a “buy” rating in a research report on Thursday, February 22nd. Finally, BTIG Research lowered their price target on shares of NeoGenomics from $25.00 to $21.00 and set a “buy” rating on the stock in a research report on Friday, December 29th. Three analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat.com, NeoGenomics presently has an average rating of “Moderate Buy” and an average target price of $19.50.

NeoGenomics Stock Performance

The firm’s fifty day moving average price is $15.08 and its 200 day moving average price is $15.89. The company has a current ratio of 6.20, a quick ratio of 5.95 and a debt-to-equity ratio of 0.57. The stock has a market capitalization of $1.81 billion, a price-to-earnings ratio of -20.31 and a beta of 1.10.

NeoGenomics (NASDAQ:NEO) last issued its quarterly earnings data on Tuesday, February 20th. The medical research company reported ($0.02) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.05. NeoGenomics had a negative net margin of 14.87% and a negative return on equity of 4.13%. The firm had revenue of $155.55 million for the quarter, compared to analyst estimates of $152.90 million. Analysts forecast that NeoGenomics, Inc. will post -0.2 EPS for the current fiscal year.

Insider Transactions at NeoGenomics

In other news, General Counsel Alicia C. Olivo sold 2,587 shares of the company’s stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $14.96, for a total value of $38,701.52. Following the transaction, the general counsel now directly owns 34,866 shares in the company, valued at approximately $521,595.36. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 1.30% of the company’s stock.

Institutional Investors Weigh In On NeoGenomics

Several large investors have recently added to or reduced their stakes in the business. Brown Advisory Inc. increased its stake in NeoGenomics by 16.9% during the 4th quarter. Brown Advisory Inc. now owns 9,643,599 shares of the medical research company’s stock worth $156,033,000 after buying an additional 1,397,397 shares during the period. First Light Asset Management LLC increased its position in shares of NeoGenomics by 29.6% in the 4th quarter. First Light Asset Management LLC now owns 3,926,756 shares of the medical research company’s stock valued at $63,535,000 after purchasing an additional 897,843 shares during the last quarter. Dimensional Fund Advisors LP increased its position in shares of NeoGenomics by 0.6% in the 4th quarter. Dimensional Fund Advisors LP now owns 3,006,523 shares of the medical research company’s stock valued at $48,650,000 after purchasing an additional 18,603 shares during the last quarter. Schroder Investment Management Group increased its position in shares of NeoGenomics by 26.7% in the 3rd quarter. Schroder Investment Management Group now owns 2,513,307 shares of the medical research company’s stock valued at $30,914,000 after purchasing an additional 529,178 shares during the last quarter. Finally, Emerald Advisers LLC increased its position in shares of NeoGenomics by 16.4% in the 3rd quarter. Emerald Advisers LLC now owns 1,927,074 shares of the medical research company’s stock valued at $23,703,000 after purchasing an additional 270,855 shares during the last quarter. 98.50% of the stock is owned by hedge funds and other institutional investors.

NeoGenomics Company Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.